Friday, 19 Jul 2019

You are here

RheumNow Podcast - Death and Surgery (2-22-19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

  1. Swedish Population study shows a 2 fold higher mortality in patients with RA and MSK (SMR 2.2 & 1.5) patients with < 9 years of education compared with those with > 12 years of education. https://t.co/bjil9FAe4I
  2. A prospective clinical registry examined 1,520 deaths among 12,679 RA participants (80,502 PYs). Mortality was strongly associated with Obesity BMI >30 kg/m2; at age 30 HR: 2.00 (1.65,2.42) p<0.001]. https://t.co/T2VIJgdO0F
  3. Review of 541,744 total knee replacement (TKR) in Australia (1999-2017) finds lower revision rates in RA vs. OA, but increased risk of infection in RA (esp. males) https://t.co/rIpSFWSNfY 
  4. Finnish population study of 4180 JIA patients shows JIA mortality not increased (0.6%) vs Nl population. Mean age at death 20.3 yrs; Most common JIA cause was accidents, vs. suicide in controls. JIA pts had less substance abuse and depression https://t.co/9WiJJPxChR     
  5. More than half (53%) of hospital deaths are from sepsis and sepsis is the most common immediate cause of death (35%) according to a medical record review from 6 academic centers https://t.co/Sp5rFTbg3m 
  6. Lupus Microbiome May Drive Disease Activity   http://rheumnow.com/content/lupus-microbiome-may-drive-disease-activity
  7. Safety Warnings for Higher Dose Tofacitinib 
  8. Hip Replacements Lasting 25 Years   
  9. Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Don’t Take My Advice (7.19.19)

Dr. Jack Cush reports the news and new journal articles from the past week on RheumNow.com.

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

EULAR 2019 – Day 3 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.